硕世生物
(688399)
| 流通市值：39.71亿 | | | 总市值：39.71亿 |
| 流通股本：5667.01万 | | | 总股本：5667.01万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 91,608,367.51 | 349,608,940.74 | 268,088,026.64 | 177,448,258.24 |
| 营业收入 | 91,608,367.51 | 349,608,940.74 | 268,088,026.64 | 177,448,258.24 |
| 二、营业总成本 | 102,757,882.33 | 420,490,233 | 308,029,355.8 | 196,326,361.15 |
| 营业成本 | 38,539,428.43 | 131,954,198.13 | 92,059,556.32 | 56,552,762.69 |
| 税金及附加 | 1,748,315.49 | 6,723,295.14 | 5,089,106.44 | 3,411,911.82 |
| 销售费用 | 30,480,848.9 | 131,328,069.26 | 98,044,768.7 | 65,516,664.68 |
| 管理费用 | 15,114,741.55 | 82,571,362.28 | 57,461,952.57 | 40,110,150.14 |
| 研发费用 | 19,092,486 | 100,886,641.37 | 72,683,955.39 | 46,770,081.96 |
| 财务费用 | -2,217,938.04 | -32,973,333.18 | -17,309,983.62 | -16,035,210.14 |
| 其中:利息费用 | 2,099,332.24 | 7,745,925.46 | 6,058,463.83 | 3,904,453.59 |
| 其中:利息收入 | 4,264,203.93 | 39,779,406.31 | 25,012,189.09 | 20,007,329.37 |
| 加:公允价值变动收益 | 10,042,281.76 | 2,182,658.64 | -6,501,055.88 | -3,951,763.43 |
| 加:投资收益 | 1,460,090.43 | -1,350,660.89 | -828,605.01 | -2,073,654.58 |
| 资产处置收益 | 254,606.27 | 2,223,291.77 | 2,221,823.99 | 1,556,757.11 |
| 资产减值损失(新) | -404,167.43 | -25,015,532.3 | -2,226,271.05 | -2,166,632.46 |
| 信用减值损失(新) | 3,587,137.35 | 36,107,911.71 | 31,058,163.92 | 23,970,128.38 |
| 其他收益 | 10,199,412.14 | 65,548,152.45 | 49,265,618.56 | 34,393,911.48 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 13,989,845.7 | 8,814,529.12 | 33,048,345.37 | 32,850,643.59 |
| 加:营业外收入 | 0.03 | 788,607.93 | 128,835.49 | 128,835.35 |
| 减:营业外支出 | 27,288.41 | 5,415,932.9 | 939,725.57 | 563,392.37 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 13,962,557.32 | 4,187,204.15 | 32,237,455.29 | 32,416,086.57 |
| 减:所得税费用 | 1,143,125.42 | 6,188,899.96 | 5,122,798 | 3,175,566.67 |
| 六、净利润 | 12,819,431.9 | -2,001,695.81 | 27,114,657.29 | 29,240,519.9 |
| 持续经营净利润 | 12,819,431.9 | -2,001,695.81 | 27,114,657.29 | 29,240,519.9 |
| 归属于母公司股东的净利润 | 12,819,431.9 | -2,001,695.81 | 27,114,657.29 | 29,240,519.9 |
| (一)基本每股收益 | 0.23 | -0.03 | 0.46 | 0.5 |
| (二)稀释每股收益 | 0.23 | -0.03 | 0.46 | 0.5 |
| 八、其他综合收益 | - | -4,982,289.21 | - | - |
| 归属于母公司股东的其他综合收益 | - | -4,982,289.21 | - | - |
| 九、综合收益总额 | 12,819,431.9 | -6,983,985.02 | 27,114,657.29 | 29,240,519.9 |
| 归属于母公司股东的综合收益总额 | 12,819,431.9 | -6,983,985.02 | 27,114,657.29 | 29,240,519.9 |
| 公告日期 | 2025-04-30 | 2025-04-19 | 2024-10-26 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |